# Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

> **NCT00513578** · PHASE2 · UNKNOWN · sponsor: **The Vaccine Company** · enrollment: 30 (estimated)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **BIOLOGICAL:** PR1 leukemia peptide vaccine
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** sargramostim

## Key facts

- **NCT ID:** NCT00513578
- **Lead sponsor:** The Vaccine Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-01
- **Primary completion:** 2009-01
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2014-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00513578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00513578, "Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00513578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*